Skip to main content

Treatment of Large and Advanced Hepatocellular Carcinoma

This is a preview of subscription content, access via your institution.

Fig. 1.
Fig. 2.

References

  1. 1.

    Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334:693–9

    PubMed  Article  CAS  Google Scholar 

  2. 2.

    Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35:1164–71

    PubMed  Article  CAS  Google Scholar 

  3. 3.

    Llovet JM, Bustamante J, Castells A, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 1999; 29:62–7

    PubMed  Article  CAS  Google Scholar 

  4. 4.

    Pawlik TM, Delman KA, Vauthey JN, et al. Tumor size predicts vascular invasion and histologic grade: implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transpl 2005; 11:1086–92

    PubMed  Article  Google Scholar 

  5. 5.

    Vauthey JN, Lauwers GY, Esnaola NF, et al. Simplified staging for hepatocellular carcinoma. J Clin Oncol 2002; 20:1527–36

    PubMed  Article  Google Scholar 

  6. 6.

    Jonas S, Bechstein WO, Steinmuller T, et al. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology 2001; 33:1080–6

    PubMed  Article  CAS  Google Scholar 

  7. 7.

    Pawlik TM, Poon RT, Abdalla EK, et al. Critical appraisal of the clinical and pathologic predictors of survival after resection of large hepatocellular carcinoma. Arch Surg 2005; 140:450–7

    PubMed  Article  Google Scholar 

  8. 8.

    Liu CL, Fan ST, Cheung ST, et al. Anterior approach versus conventional approach right hepatic resection for large hepatocellular carcinoma: a prospective randomized controlled study. Ann Surg 2006; 244:194–203

    PubMed  Article  Google Scholar 

  9. 9.

    Belghiti J, Guevara OA, Noun R, et al. Liver hanging maneuver: a safe approach to right hepatectomy without liver mobilization. J Am Coll Surg 2001; 193:109–11

    PubMed  Article  CAS  Google Scholar 

  10. 10.

    Ogata S, Belghiti J, Varma D, et al. Two hundred liver hanging maneuvers for major hepatectomy: a single-center experience. Ann Surg 2007; 245:31–5

    PubMed  Article  Google Scholar 

  11. 11.

    Yoshioka H, Sato M, Sonomura T, et al. Factors associated with survival exceeding 5 years after transcatheter arterial embolization for hepatocellular carcinoma. Semin Oncol 1997; 24:S6–29–S26–37

    Google Scholar 

  12. 12.

    O’Suilleabhain CB, Poon RT, Yong JL, et al. Factors predictive of 5-year survival after transarterial chemoembolization for inoperable hepatocellular carcinoma. Br J Surg 2003; 90:325–31

    PubMed  Article  CAS  Google Scholar 

  13. 13.

    Molmenti EP, Klintmalm GB. Liver transplantation in association with hepatocellular carcinoma: an update of the International Tumor Registry. Liver Transpl 2002; 8:736–48

    PubMed  Article  Google Scholar 

  14. 14.

    Figueras J, Jaurrieta E, Valls C, et al. Survival after liver transplantation in cirrhotic patients with and without hepatocellular carcinoma: a comparative study. Hepatology 1997; 25:1485–89

    PubMed  Article  CAS  Google Scholar 

  15. 15.

    Hemming AW, Cattral MS, Reed AI, et al. Liver transplantation for hepatocellular carcinoma. Ann Surg 2001; 233:652–9

    PubMed  Article  CAS  Google Scholar 

  16. 16.

    Yoo HY, Patt CH, Geschwind JF, Thuluvath PJ. The outcome of liver transplantation in patients with hepatocellular carcinoma in the United States between 1988 and 2001: 5-year survival has improved significantly with time. J Clin Oncol 2003; 21:4329–35

    PubMed  Article  Google Scholar 

  17. 17.

    Yamamoto J, Iwatsuki S, Kosuge T, et al. Should hepatomas be treated with hepatic resection or transplantation? Cancer 1999; 86:1151–58

    PubMed  Article  CAS  Google Scholar 

  18. 18.

    Llovet JM, Fuster J, Bruix J. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl 2004; 10:S115–20

    PubMed  Article  Google Scholar 

  19. 19.

    Nagasue N, Kohno H, Chang YC, et al. Liver resection for hepatocellular carcinoma. Results of 229 consecutive patients during 11 years. Ann Surg 1993; 217:375–84

    PubMed  Article  CAS  Google Scholar 

  20. 20.

    Poon RT, Fan ST. Evaluation of the new AJCC/UICC staging system for hepatocellular carcinoma after hepatic resection in Chinese patients. Surg Oncol Clin North Am 2003; 12:35–50, viii

    Article  Google Scholar 

  21. 21.

    Vauthey JN, Klimstra D, Franceschi D, et al. Factors affecting long-term outcome after hepatic resection for hepatocellular carcinoma. Am J Surg 1995; 169:28–34

    PubMed  Article  CAS  Google Scholar 

  22. 22.

    Ng KK, Vauthey JN, Pawlik TM, et al. Is hepatic resection for large or multinodular hepatocellular carcinoma justified? Results from a multi-institutional database. Ann Surg Oncol 2005; 12:364–73

    PubMed  Article  Google Scholar 

  23. 23.

    Nakashima T, Kojiro M. Pathologic characteristics of hepatocellular carcinoma. Semin Liver Dis 1986; 6:259–66

    PubMed  CAS  Article  Google Scholar 

  24. 24.

    Minagawa M, Makuuchi M, Takayama T, et al. Selection criteria for hepatectomy in patients with hepatocellular carcinoma and portal vein tumor thrombus. Ann Surg 2001; 233:379–84

    PubMed  Article  CAS  Google Scholar 

  25. 25.

    Groupe d’Etude et de Traitement du Carcinome Hepatocellulaire. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 1995; 332:1256–61

    Article  Google Scholar 

  26. 26.

    Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359:1734–9

    PubMed  Article  Google Scholar 

  27. 27.

    Takayasu K, Arii S, Ikai I, et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 2006; 131:461–9

    PubMed  Article  CAS  Google Scholar 

  28. 28.

    Lladó L, Virgili J, Figueras J, et al. A prognostic index of the survival of patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization. Cancer 2000; 88:50–7

    PubMed  Article  Google Scholar 

  29. 29.

    Pacella CM, Bizzarri G, Cecconi P, et al. Hepatocellular carcinoma: long-term results of combined treatment with laser thermal ablation and transcatheter arterial chemoembolization. Radiology 2001; 219:669–78

    PubMed  CAS  Google Scholar 

  30. 30.

    Veltri A, Moretto P, Doriguzzi A, et al. Radiofrequency thermal ablation (RFA) after transarterial chemoembolization (TACE) as a combined therapy for unresectable non-early hepatocellular carcinoma (HCC). Eur Radiol 2006; 16:661–9

    PubMed  Article  Google Scholar 

  31. 31.

    Wu F, Wang ZB, Chen WZ, et al. Advanced hepatocellular carcinoma: treatment with high-intensity focused ultrasound ablation combined with transcatheter arterial embolization. Radiology 2005; 235:659–67

    PubMed  Article  Google Scholar 

  32. 32.

    Raoul JL, Guyader D, Bretagne JF, et al. Randomized controlled trial for hepatocellular carcinoma with portal vein thrombosis: intra-arterial iodine–131-iodized oil versus medical support. J Nucl Med 1994; 35:1782–7

    PubMed  CAS  Google Scholar 

  33. 33.

    Uraki J, Yamakado K, Nakatsuka A, Takeda K. Transcatheter hepatic arterial chemoembolization for hepatocellular carcinoma invading the portal veins: therapeutic effects and prognostic factors. Eur J Radiol 2004; 51:12–8

    PubMed  Article  Google Scholar 

  34. 34.

    Obi S, Yoshida H, Toune R, et al. Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion. Cancer 2006; 106:1990–7

    PubMed  Article  CAS  Google Scholar 

  35. 35.

    Houle S, Yip TK, Shepherd FA, et al. Hepatocellular carcinoma: pilot trial of treatment with Y-90 microspheres. Radiology 1989; 172:857–60

    PubMed  CAS  Google Scholar 

  36. 36.

    Shepherd FA, Rotstein LE, Houle S, et al. A phase I dose escalation trial of yttrium-90 microspheres in the treatment of primary hepatocellular carcinoma. Cancer 1992; 70:2250–4

    PubMed  Article  CAS  Google Scholar 

  37. 37.

    Andrews JC, Walker SC, Ackermann RJ, et al. Hepatic radioembolization with yttrium-90 containing glass microspheres: preliminary results and clinical follow-up. J Nucl Med 1994; 35:1637–44

    PubMed  CAS  Google Scholar 

  38. 38.

    Dancey JE, Shepherd FA, Paul K, et al. Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres. J Nucl Med 2000; 41:1673–81

    PubMed  CAS  Google Scholar 

  39. 39.

    Lau WY, Leung WT, Ho S, et al. Treatment of inoperable hepatocellular carcinoma with intrahepatic arterial yttrium-90 microspheres: a phase I and II study. Br J Cancer 1994; 70:994–9

    PubMed  CAS  Google Scholar 

  40. 40.

    Lau WY, Ho S, Leung TW, et al. Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres. Int J Radiat Oncol Biol Phys 1998; 40:583–92

    PubMed  CAS  Google Scholar 

  41. 41.

    Carr BI. Hepatic arterial 90 yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients. Liver Transpl 2004; 10:S107–10

    PubMed  Article  Google Scholar 

  42. 42.

    Geschwind JF, Salem R, Carr BI, et al. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology 2004; 127:S194–205

    PubMed  Article  CAS  Google Scholar 

  43. 43.

    Lau WY, Ho S, Leung WT, et al. What determines survival duration in hepatocellular carcinoma treated with intraarterial Yttrium-90 microspheres? Hepatogastroenterology 2001; 48:338–40

    PubMed  CAS  Google Scholar 

  44. 44.

    Goin JE, Salem R, Carr BI, et al. Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: factors associated with liver toxicities. J Vasc Interv Radiol 2005; 16:205–13

    PubMed  Google Scholar 

  45. 45.

    Salem R, Lewandowski RJ, Atassi B, et al. Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival. J Vasc Interv Radiol 2005; 16:1627–39

    PubMed  Google Scholar 

  46. 46.

    Goin J, Roberts C. Comparison of post-embolization syndrome in the treatment of patients with unresectable hepatocellular carcinoma: Trans-catheter arterial chemo-embolization versus yttrium-90 glass microspheres. World J Nuc Med 2004; 49–56

  47. 47.

    Leung TW, Johnson PJ. Systemic therapy for hepatocellular carcinoma. Semin Oncol 2001; 28:514–20

    PubMed  Article  CAS  Google Scholar 

  48. 48.

    Yeo W, Mok TS, Zee B, et al. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 2005; 97:1532–8

    PubMed  CAS  Article  Google Scholar 

  49. 49.

    Lau WY, Leung TW, Lai BS, et al. Preoperative systemic chemoimmunotherapy and sequential resection for unresectable hepatocellular carcinoma. Ann Surg 2001; 233:236–41

    PubMed  Article  CAS  Google Scholar 

  50. 50.

    Leung TW, Tang AM, Zee B, et al. Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy. Cancer 2002; 94:421–7

    PubMed  Article  CAS  Google Scholar 

  51. 51.

    Llovet J, Ricci S, Mazzaferro V, et al. Sorafenib improves survival in advanced hepatocellular carcinoma (HCC): Results of a phase III randomized placebo-controlled trial (SHARP trial). J Clin Oncol 2007; 25:LBA1

    Google Scholar 

  52. 52.

    Abou-Alfa GK, Schwartz L, Ricci S, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006; 24:4293–300

    PubMed  Article  CAS  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Guido Torzilli MD, PhD.

Additional information

Proceedings of the 5th International Meeting Hepatocellular Carcinoma: Eastern and Western Experiences held in Houston, TX, January 11-13, 2007.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Abdalla, E.K., Denys, A., Hasegawa, K. et al. Treatment of Large and Advanced Hepatocellular Carcinoma. Ann Surg Oncol 15, 979–985 (2008). https://doi.org/10.1245/s10434-007-9727-7

Download citation

Keywords

  • HCC
  • Large
  • Multinodular
  • Advanced
  • Chemoembolization
  • Microsphere
  • Systemic therapy